XML 125 R102.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Contingencies and commitments (Details Textual) $ in Millions |  |  |  |  |  |  |  |  |  |  |  | 1 Months Ended | 2 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Jan. 22, 2018 lawsuit | Oct. 18, 2017 patent | Oct. 06, 2017 patent | Oct. 05, 2017 defendants | Sep. 22, 2017 USD ($) | Sep. 14, 2017 lawsuit | Jan. 23, 2017 patent | Nov. 08, 2016 lawsuit | Nov. 01, 2016 lawsuit | Feb. 26, 2016 patent affiliate | Dec. 15, 2014 patent | Dec. 31, 2017 USD ($) lawsuit | Jun. 30, 2017 lawsuit | Sep. 30, 2016 lawsuit | Mar. 31, 2016 | Oct. 02, 2015 lawsuit | Dec. 31, 2017 USD ($) actions plaintiffs lawsuit | Dec. 31, 2016 USD ($) | Dec. 31, 2015 USD ($)
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Future rental commitments for abandoned leases | $ |  |  |  |  |  |  |  |  |  |  |  | $ 264 |  |  |  |  | $ 264 |  |
Future rental income relating to noncancelable subleases of abandoned facilities | $ |  |  |  |  |  |  |  |  |  |  |  | $ 205 |  |  |  |  | 205 |  |
Rental expense on operating leases | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 159 | $ 134 | $ 133
Sanofi/Regeneron Patent Litigation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of patents allegedly infringed | patent |  |  |  |  |  |  |  |  |  |  | 7 |  |  |  |  |  |  |  |
Length of trial |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5 days |  |  |  |
Loss contingency, number of defendants | defendants |  |  |  | 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sensipar (cinacalcet) Patent Litigation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of lawsuits filed | lawsuit |  |  |  |  |  |  |  |  |  |  |  | 4 | 4 | 14 |  |  |  |  |
KYPROLIS (carfilzomib) Patent Litigation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of lawsuits filed | lawsuit |  |  |  |  |  | 3 |  |  |  |  |  |  |  |  |  |  | 10 |  |
Apotex NEUPOGEN/Neulasta [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of lawsuits filed | lawsuit |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2 |  |  |
ENBREL (etanercept) [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of patents allegedly infringed | patent |  |  |  |  |  |  |  |  |  | 5 |  |  |  |  |  |  |  |  |
Gain contingency, number of affiliates | affiliate |  |  |  |  |  |  |  |  |  | 2 |  |  |  |  |  |  |  |  |
Epoetin Alfa Litigation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of patents allegedly infringed | patent |  |  |  |  |  |  | 2 |  |  |  |  |  |  |  |  |  |  |  |
Length of trial |  |  |  |  | 5 days |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aount awarded from other party | $ |  |  |  |  | $ 70 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Mvasi Patent Litigation, Genentech, Inc. (Genentech) and the City of Hope [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of patents allegedly infringed | patent |  |  | 27 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency, patents allegedly infringed | patent |  | 25 | 24 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
State Derivative Litigation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency, number of plaintiffs | plaintiffs |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3 |  |
Loss contingency, number of lawsuits | actions |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1 |  |
Onyx Therapeutics, Inc [Member] | KYPROLIS (carfilzomib) Patent Litigation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of lawsuits filed | lawsuit |  |  |  |  |  |  |  | 4 | 4 |  |  |  |  |  |  |  |  |  |
Subsequent event [Member] | Mvasi Patent Litigation, Genentech, Inc. (Genentech) and the City of Hope [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of lawsuits filed | lawsuit | 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition Future rental commitments for abandoned leases. + References No definition available. + Details
Name: | amgn_FutureRentalCommitmentsForAbandonedLeases
Namespace Prefix: | amgn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Gain Contingency, Number of Affiliates + References No definition available. + Details
Name: | amgn_GainContingencyNumberofAffiliates
Namespace Prefix: | amgn_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Gain Contingency, Number of Lawsuits Filed + References No definition available. + Details
Name: | amgn_GainContingencyNumberofLawsuitsFiled
Namespace Prefix: | amgn_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Litigation Settlement, Length of Trial + References No definition available. + Details
Name: | amgn_LitigationSettlementLengthofTrial
Namespace Prefix: | amgn_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Rental expense incurred for assets leased under operating leases including furniture and equipment included in operating expenses. + References No definition available. + Details
Name: | amgn_RentalExpenseOnOperatingLeases
Namespace Prefix: | amgn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of entity's patents that another entity has allegedly infringed. + References No definition available. + Details
Name: | us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount awarded from other party in judgment or settlement of litigation. + References No definition available. + Details
Name: | us-gaap_LitigationSettlementAmountAwardedFromOtherParty
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_LossContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The total number of new claims filed pertaining to a loss contingency during the period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14435-108349 + Details
Name: | us-gaap_LossContingencyNewClaimsFiledNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of defendants named in a legal action. + References No definition available. + Details
Name: | us-gaap_LossContingencyNumberOfDefendants
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of plaintiffs that have filed claims pertaining to a loss contingency. + References No definition available. + Details
Name: | us-gaap_LossContingencyNumberOfPlaintiffs
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of another entity's patents that the entity has allegedly infringed. + References No definition available. + Details
Name: | us-gaap_LossContingencyPatentsAllegedlyInfringedNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Future minimum rental payments in aggregate as of the balance sheet date under operating leases. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=84164653&loc=d3e41551-112718 + Details
Name: | us-gaap_OperatingLeasesFutureMinimumPaymentsReceivable
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | us-gaap_LitigationCaseAxis=amgn_SanofiRegeneronPatentLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationCaseAxis=amgn_SensiparcinacalcetPatentLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationCaseAxis=amgn_KYPROLIScarfilzomibPatentLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationCaseAxis=amgn_ApotexNEUPOGENNeulastaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationCaseAxis=amgn_ENBRELetanerceptMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationCaseAxis=amgn_EpoetinAlfaLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationCaseAxis=amgn_MvasiPatentLitigationGenentechInc.GenentechandtheCityofHopeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationCaseAxis=amgn_StateDerivativeLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |